- Home
- JANX vs KRP Comparison
JANX vs KRP Comparison
Compare JANX & KRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- KRP
- Stock Information
- Founded
- JANX 2017
- KRP 2013
- Country
- JANX United States
- KRP United States
- Employees
- JANX N/A
- KRP N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- KRP Oil & Gas Production
- Sector
- JANX Health Care
- KRP Energy
- Exchange
- JANX Nasdaq
- KRP Nasdaq
- Market Cap
- JANX 1.4B
- KRP 1.1B
- IPO Year
- JANX 2021
- KRP 2017
- Fundamental
- Price
- JANX $23.15
- KRP $13.54
- Analyst Decision
- JANX Strong Buy
- KRP Hold
- Analyst Count
- JANX 11
- KRP 5
- Target Price
- JANX $76.55
- KRP $17.20
- AVG Volume (30 Days)
- JANX 714.6K
- KRP 469.8K
- Earning Date
- JANX 11-05-2025
- KRP 11-06-2025
- Dividend Yield
- JANX N/A
- KRP 12.40%
- EPS Growth
- JANX N/A
- KRP N/A
- EPS
- JANX N/A
- KRP N/A
- Revenue
- JANX $439,000.00
- KRP $312,566,668.00
- Revenue This Year
- JANX N/A
- KRP $9.34
- Revenue Next Year
- JANX $130.50
- KRP $2.80
- P/E Ratio
- JANX N/A
- KRP N/A
- Revenue Growth
- JANX N/A
- KRP N/A
- 52 Week Low
- JANX $21.73
- KRP $10.98
- 52 Week High
- JANX $71.71
- KRP $16.99
- Technical
- Relative Strength Index (RSI)
- JANX 48.91
- KRP 46.65
- Support Level
- JANX $21.73
- KRP $13.61
- Resistance Level
- JANX $24.54
- KRP $13.95
- Average True Range (ATR)
- JANX 1.07
- KRP 0.30
- MACD
- JANX -0.06
- KRP 0.05
- Stochastic Oscillator
- JANX 47.38
- KRP 43.58
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About KRP Kimbell Royalty Partners Common Units Representing Limited Partner Interests
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.